Thermo Fisher Scientific Inc (NYSE:TMO)‘s stock had its “buy” rating reiterated by investment analysts at Bank of America Corporation in a research note issued to investors on Friday. They presently have a $210.00 target price on the medical research company’s stock, up from their prior target price of $200.00. Bank of America Corporation’s price objective would suggest a potential upside of 15.67% from the company’s previous close.

A number of other research firms also recently issued reports on TMO. Citigroup Inc. restated a “buy” rating and set a $201.00 target price (up from $182.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 10th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $199.00 target price on the stock in a research report on Tuesday, July 11th. Barclays PLC restated an “overweight” rating and set a $200.00 target price (up from $190.00) on shares of Thermo Fisher Scientific in a research report on Monday. Wells Fargo & Company restated an “outperform” rating and set a $200.00 target price (up from $195.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 13th. Finally, BidaskClub upgraded shares of Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. One research analyst has rated the stock with a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the stock. Thermo Fisher Scientific has an average rating of “Buy” and a consensus price target of $187.88.

Shares of Thermo Fisher Scientific (NYSE TMO) opened at 181.55 on Friday. The company has a 50 day moving average of $176.35 and a 200-day moving average of $162.18. The company has a market capitalization of $71.03 billion, a P/E ratio of 33.12 and a beta of 1.06. Thermo Fisher Scientific has a 12-month low of $139.07 and a 12-month high of $182.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 26th. The medical research company reported $2.08 EPS for the quarter, topping analysts’ consensus estimates of $2.02 by $0.06. Thermo Fisher Scientific had a net margin of 11.58% and a return on equity of 15.73%. The firm had revenue of $4.77 billion for the quarter, compared to analyst estimates of $4.68 billion. During the same quarter in the prior year, the firm earned $1.80 EPS. The company’s revenue was up 10.9% on a year-over-year basis. On average, equities analysts anticipate that Thermo Fisher Scientific will post $9.23 EPS for the current fiscal year.

WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/07/21/thermo-fisher-scientific-inc-tmo-given-buy-rating-at-bank-of-america-corporation.html.

In related news, CEO Marc N. Casper sold 20,000 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $172.79, for a total value of $3,455,800.00. Following the sale, the chief executive officer now directly owns 269,279 shares in the company, valued at approximately $46,528,718.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Daniel P. Shine sold 4,688 shares of the stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $171.88, for a total transaction of $805,773.44. Following the completion of the sale, the insider now owns 29,200 shares in the company, valued at $5,018,896. The disclosure for this sale can be found here. Insiders sold a total of 28,720 shares of company stock worth $4,960,764 over the last quarter. 0.49% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the stock. Independent Portfolio Consultants Inc. increased its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the period. Sharkey Howes & Javer increased its stake in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares during the period. Washington Trust Bank increased its stake in shares of Thermo Fisher Scientific by 0.5% in the first quarter. Washington Trust Bank now owns 2,210 shares of the medical research company’s stock valued at $339,000 after buying an additional 10 shares during the period. Beacon Trust Co. increased its stake in shares of Thermo Fisher Scientific by 0.6% in the first quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock valued at $341,000 after buying an additional 12 shares during the period. Finally, Dumont & Blake Investment Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock valued at $849,000 after buying an additional 15 shares during the period. Institutional investors and hedge funds own 86.93% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.